Type 2 Diabetes Mellitus Completed Phase 2 Trials for Linagliptin (DB08882)

Also known as: T2DM / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Type Two / Type Two Diabetes Mellitus / NIDDM / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus Non-insulin-dependent / Type 2 Diabetes / Diabetes, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Type 2 Diabetes (T2D) / Diabetes Mellitus´╝îType 2 / Diabetes Mellitus. Type 2 / Diabetes Mellitus Type 2 / Diabetes Mellitus Type-2 / Type-2 Diabetes Mellitus / Diabetes Mellitus 2 Type / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus, Type 2 (T2DM) / T2DM (Type 2 Diabetes Mellitus) / Type 2 Diabetes Mellitus (T2D) / Diabetes Mellitus, Type 2 / Type-2 Diabetes / Diabetes Type 2 / Type 2 Diabetes (T2DM) / Type II Diabetes / Diabetes, Type II / Type-II Diabetes Mellitus / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / Diabetes Type II / Type II; Diabetes / Diabetes Mellitus Type II / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

IndicationStatusPhase
DBCOND0029752 (Type 2 Diabetes Mellitus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02183324BI 1356 BS in Japanese Patients With Type 2 Diabetes MellitusTreatment
NCT01342484Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 DiabetesTreatment
NCT01012037Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 DiabetesTreatment
NCT00716092The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic PatientsTreatment
NCT00328172Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes PatientsTreatment
NCT00309608Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 DiabetesTreatment